Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3 , can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors In Vitro Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM; 24 h) down-regulates the transcription factors Oct 4, Sox 2 and Nanog of mESCs. Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM) inhibits integrin gene expression mESC-col I (type I collagen) constructs. Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM)-treated mESC leads to the formation of aggregates and detachment from the surface. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: MESCs Concentration: 0.5 mM Incubation Time: 24 h Result: Down-regulated Oct 4, Nanog, Sox 2 by 99%, 97.5%, and 90% respectively. Up-regulated Rex1 gene expression. In Vivo Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM, 24 h)-treated mESCs in the presence/absence of Leukemia inhibitory factor (LIF) (injected in both thighs) generated teratomas in severe combined immunodeficiency (SCID) mice, which indicates that the process of mESC tumor formation in vivo is dependent on integrin interaction . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:αvβ3